PL3938040T3 - Witamina K2 w kombinacji z antykoagulantami do stosowania w leczeniu bolesności mięśni - Google Patents

Witamina K2 w kombinacji z antykoagulantami do stosowania w leczeniu bolesności mięśni

Info

Publication number
PL3938040T3
PL3938040T3 PL20717988.8T PL20717988T PL3938040T3 PL 3938040 T3 PL3938040 T3 PL 3938040T3 PL 20717988 T PL20717988 T PL 20717988T PL 3938040 T3 PL3938040 T3 PL 3938040T3
Authority
PL
Poland
Prior art keywords
anticoagulants
vitamin
combination
treating muscle
muscle soreness
Prior art date
Application number
PL20717988.8T
Other languages
English (en)
Inventor
Rick VAN GORP
Original Assignee
Lesaffre Et Compagnie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lesaffre Et Compagnie filed Critical Lesaffre Et Compagnie
Publication of PL3938040T3 publication Critical patent/PL3938040T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • A61K31/122Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/422Oxazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
PL20717988.8T 2019-03-12 2020-03-11 Witamina K2 w kombinacji z antykoagulantami do stosowania w leczeniu bolesności mięśni PL3938040T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962817037P 2019-03-12 2019-03-12
PCT/NO2020/050066 WO2020185092A2 (en) 2019-03-12 2020-03-11 Use of vitamin k in combination with anticoagulants

Publications (1)

Publication Number Publication Date
PL3938040T3 true PL3938040T3 (pl) 2025-07-14

Family

ID=70228770

Family Applications (1)

Application Number Title Priority Date Filing Date
PL20717988.8T PL3938040T3 (pl) 2019-03-12 2020-03-11 Witamina K2 w kombinacji z antykoagulantami do stosowania w leczeniu bolesności mięśni

Country Status (13)

Country Link
US (2) US20200289521A1 (pl)
EP (1) EP3938040B1 (pl)
JP (2) JP7615044B2 (pl)
CN (2) CN117414431A (pl)
AU (3) AU2020236308B2 (pl)
BR (1) BR112021018002A2 (pl)
CA (2) CA3255246A1 (pl)
CL (3) CL2021002363A1 (pl)
IL (2) IL314746A (pl)
MX (3) MX2021010977A (pl)
PL (1) PL3938040T3 (pl)
WO (1) WO2020185092A2 (pl)
ZA (2) ZA202106359B (pl)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ583069A (en) * 2007-07-24 2012-06-29 Viridis Biopharma Pvt Ltd Treatments using vitamin k analogues and derivatives
US8211947B2 (en) * 2008-01-28 2012-07-03 Guillermo Selman-Housein Sosa Composition and method for treating and preventing musculoskeletal and connective tissue disorders
WO2010103545A2 (en) * 2009-03-12 2010-09-16 Viridis Biopharma Pvt Ltd, Method of use of vitamin k as energy enhancer in diverse disease states
EP2886129A1 (en) * 2013-12-20 2015-06-24 VitaK B.V. Prevention and counteraction of diet-induced thrombosis risk
EP3801477A4 (en) * 2018-06-08 2022-02-23 Epizon Pharma, Inc. METHODS AND COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF TISSUE CALCIFICATION

Also Published As

Publication number Publication date
EP3938040B1 (en) 2025-05-21
CN113557032A (zh) 2021-10-26
CL2024001729A1 (es) 2024-10-18
AU2024216503B2 (en) 2025-10-30
US20220160652A1 (en) 2022-05-26
ZA202209447B (en) 2024-05-30
CN117414431A (zh) 2024-01-19
BR112021018002A2 (pt) 2021-11-16
CA3255246A1 (en) 2025-05-28
EP3938040A2 (en) 2022-01-19
US20200289521A1 (en) 2020-09-17
WO2020185092A3 (en) 2020-11-12
NZ781054A (en) 2025-05-02
CL2021002363A1 (es) 2022-06-10
EP3938040C0 (en) 2025-05-21
MX2024007166A (es) 2024-06-26
ZA202106359B (en) 2023-08-30
MX2021010977A (es) 2021-12-10
CL2023003790A1 (es) 2024-07-26
AU2024216508B2 (en) 2025-10-30
JP7615044B2 (ja) 2025-01-16
AU2020236308A1 (en) 2021-11-04
IL286245A (en) 2021-10-31
JP2022524619A (ja) 2022-05-09
WO2020185092A2 (en) 2020-09-17
AU2024216508A1 (en) 2024-09-19
IL314746A (en) 2024-10-01
AU2020236308B2 (en) 2024-10-10
MX2024007164A (es) 2024-06-26
CA3132245A1 (en) 2020-09-17
JP2024050759A (ja) 2024-04-10
AU2024216503A1 (en) 2024-09-19

Similar Documents

Publication Publication Date Title
PL3882250T3 (pl) Amino-pirolopirymidynon tetrahydropiranylu do stosowania w leczeniu zaburzeń mediowanych przez btk
IL272596A (en) Pridopidine for use in the treatment of ALS
IL255780A (en) Therapeutic combinations and methods for treating neoplasia
IL254142B (en) Tredifitant for use in the treatment of a disease or medical condition that responds to Tredifitent
LT4119569T (lt) Konjuguoti priešprasmiai junginiai, skirti panaudoti terapijoje
ZA201900343B (en) Self-contained treatment unit for haemodialysis treatments
IL284053A (en) New compounds and their use in therapy
IL256135A (en) Antibodies against human csf-1r for use in inducing lymphocytosis in lymphomas or leukemias
IL273470A (en) Semaglutide in medical treatment
GB201503967D0 (en) Biocompatible implants for use in tendon therapy
EP3151932A4 (en) Exercise device for blood circulation and metabolism in the knee
PT3283064T (pt) Derivados úteis para o tratamento da atrofia muscular
SMT202200221T1 (it) Medicinale per l'uso nel trattamento della gotta
GB201821147D0 (en) Mirna for use in therapy
GB2592803B (en) Compounds for use in preventing or treating athlete overtraining
HUE045185T2 (hu) Új terápiás vegyület és terápiában történõ alkalmazása
ZA201907017B (en) Combination therapy for use in treating retroviral infection
PL3938040T3 (pl) Witamina K2 w kombinacji z antykoagulantami do stosowania w leczeniu bolesności mięśni
GB2539742B (en) Therapeutic treatment methods, and apparatus for use therein
GB201615844D0 (en) Agents for use in therapy
GB2510477B (en) Formulations for use in the treatment of chronic fatigue and associated conditions, etc
IL268265B (en) 3-beta-hydroxy-5-alpha-paragnane-20-one for use in medical treatment
GB201702652D0 (en) Delta-theraphotoxin-Ac1 for use in treating diabetes
GB201512260D0 (en) Improvements in or relating to beauty, health, or therapeutic treatments
GB2553684B (en) Ethynylxanthines, preparation and use for cancer treatment